SCHEMBL5732744

SCHEMBL5732744

CCOP(=O)(O)CC(=O)c1cccc(COc2ccccc2)c1

nearest known ligand 0.56

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MRGPRX4 Q96LA9 9/20 0.56
SMN1; SMN2 Q16637 6/20 0.56
TP53 P04637 3/20 0.56
PKM P14618 2/20 0.56
NFKB1 P19838 2/20 0.56
NFKB2 Q00653 2/20 0.56
RELA Q04206 2/20 0.56
RAB9A P51151 5/20 0.52
NPC1 O15118 4/20 0.52
LMNA P02545 2/20 0.52
RXFP1 Q9HBX9 1/20 0.50
F10 P00742 1/20 0.49
MAOB P27338 1/20 0.49
PTPN1 P18031 1/20 0.48
NR4A2 P43354 1/20 0.48
ALDH1A1 P00352 2/20 0.47
KDM4E B2RXH2 1/20 0.47
SMPD1 P17405 1/20 0.47
CETP P11597 1/20 0.46
POLB P06746 1/20 0.46

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6490457 0.93 MAOB (0.59) MRGPRX4SMN1; SMN2TP53PKMNFKB1
SCHEMBL5734543 0.85 LMNA (0.42) MRGPRX4SMN1; SMN2TP53PKMNFKB1
SCHEMBL5734501 0.84 KMT2A (0.46) SMN1; SMN2RAB9ANPC1LMNAMAOB
SCHEMBL5734228 0.83 CYP4F2 (0.42) MRGPRX4SMN1; SMN2TP53PKMNFKB1
SCHEMBL5733094 0.83 ERCC5 (0.53) SMN1; SMN2PKMRAB9ANPC1LMNA
SCHEMBL5733422 0.82 RAB9A (0.51) SMN1; SMN2TP53RAB9ANPC1LMNA
SCHEMBL5732739 0.81 MRGPRX4 (0.56) MRGPRX4SMN1; SMN2TP53PKMNFKB1
SCHEMBL5733025 0.81 KAT6A (0.43) MRGPRX4SMN1; SMN2TP53PKMNFKB1
SCHEMBL5734845 0.80 POLB (0.57) SMN1; SMN2RAB9ANPC1LMNAPTPN1
SCHEMBL5734479 0.80 L3MBTL1 (0.50) LMNAALDH1A1POLBHTT

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1409455-B1 PROSTAGLANDIN ANALOGUES-AS EP4 RECEPTOR AGONISTS HOFFMANN LA ROCHE (CH) 2006-01-04 EP disclosed
US-6900336-B2 8-aza-11-deoxy prostaglandin analogues SYNTEX (U.S.A.) LLC (US) 2005-05-31 US disclosed
EP-1409455-A1 PROSTAGLANDIN ANALOGUES-AS EP4 RECEPTOR AGONISTS F. HOFFMANN-LA ROCHE AG (CH) 2004-04-21 EP disclosed
US-20030120079-A1 Such as 7-((R)-2-((E)-3-(3-Benzyl-phenyl)-3-hydroxy-propenyl)-5-oxo-pyrrolidin-1-yl)-heptanoic acid; side effects reduction SYNTEX (U.S.A.) LLC 2003-06-26 US disclosed
WO-2003008377-A1 PROSTAGLANDIN ANALOGUES_AS EP4 RECEPTOR AGONISTS F. HOFFMANN-LA ROCHE AG (CH) 2003-01-30 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20030120079-A1 Such as 7-((R)-2-((E)-3-(3-Benzyl-phenyl)-3-hydroxy-propenyl)-5-oxo-pyrrolidin-1-yl)-heptanoic acid; side effects reduction PTGER4, FFAR4, PTGER1 MRGPRX4 218/4885SMN1; SMN2 4413/4885TP53 4864/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.